Wuxi Griffin has recently completed construction of their 2,550 m2 filling facility in Wuxi, China. It is a Swedish and a Chinese company that have joined forces in this new project. The new contract manufacturer Wuxi Griffin will focus on providing aseptic filling services globally to western GMP standards. Products to be manufactured in the new facility include MAbs, vaccine, recombinant proteins as well as biosimilars and small molecule drugs (traditional). RABS and Isolator production technology is in place for…

Pharmaceuticals GmbH (CEVEC) announced the introduction of a new solution for scalable stable viral vector production for gene therapy applications. Dr. Nicole Faust, CEO & CSO of CEVEC presented data from the Company’s successful proof-of-concept studies with these newly introduced cell lines on January 24, 2018 at Phacilitate. Based on its proprietary CAP-GT manufacturing platform of suspension cell lines, CEVEC has successfully developed a novel AAV (adeno-associated virus) stable production system that allows for easy scale up in all existing…